Sounds to me like Relenza has captured over 50% market share in Japan based on increased resistence to Tamiflu. Bodes well for global sales, and the fact that GSK are actively promoting the drug. Perhaps the Boad of Directors made the right call after all...
I'm really excited about Biota's future, Relenza should help finance the pipeline and LANI should be coming this year. Can't believe the stock is still sub $1.
